What's Happening?
Huxley Medical, a medical technology company, has announced the expansion of its SANSA diagnostic platform with the introduction of SANSA GO, a point-of-care enrollment model, and a new cardiovascular risk marker called hypoxic burden. SANSA GO allows
clinics to dispense the SANSA device during patient visits, enhancing workflow flexibility by offering both clinic and home access models. The platform, which has been used by over a thousand physicians since its U.S. release in 2025, is the only multi-diagnostic monitor that can assess electrocardiograms (ECG), obstructive sleep apnea, and central sleep apnea with a single chest-worn patch. The addition of hypoxic burden provides further cardiovascular insights, particularly for patients with conditions like atrial fibrillation. The new tools aim to streamline care and provide actionable information across multiple disease states.
Why It's Important?
The expansion of the SANSA platform is significant as it addresses the growing demand for comprehensive diagnostic solutions in sleep apnea and cardiovascular health. By integrating point-of-care and home testing capabilities, SANSA GO enhances accessibility and efficiency in patient care. This is particularly important as treatment options for sleep apnea diversify, including therapies that impact sleep, metabolic, and cardiovascular health. The ability to assess both sleep and cardiac health with a single device can lead to more informed care decisions and potentially improve patient outcomes. The introduction of hypoxic burden as a cardiovascular risk marker further strengthens the platform's utility in managing complex health conditions.
What's Next?
SANSA GO and the hypoxic burden marker will become commercially available nationwide during the SLEEP 2026 meeting of the Associated Professional Sleep Societies in Baltimore, Maryland, from June 14-17. This rollout is expected to enhance the adoption of the SANSA platform across various healthcare settings. As more clinics integrate these tools, there may be increased collaboration between primary care and cardiology to optimize patient management. The ongoing presentation of study findings and clinical feedback will likely influence future developments and enhancements to the platform.
